IgA nephropathy: What patients are at risk of progression to end-stage renal disease and how should they be treated? Manuel Praga, Fernando Caravaca, Claudia Yuste, Teresa Cavero, Eduardo Hernández, Enrique Morales, Eva Mérida, Juan Antonio Moreno, Angel Sevillano, Eduardo Gutiérrez

IMMUNOGLOBULIN THERAPY AND IgA NEPHROPATHY Eduardo Gutiérrez, Eduardo Hernández, Enrique Morales, Manuel Praga

Progress in understanding the pathogenesis of IgA nephropathy: New perspectives for the near future? Segarra